News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Kim M. Hirshfield

Articles by Kim M. Hirshfield

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

BySara M. Tolaney, MD, MPH,Paolo D’Amico,Liyi Jia,Kim M. Hirshfield,Fatima Cardoso

April 16th 2025

Latest Updated Articles

Trending on CancerNetwork

Novel Cancer Vaccine Receives FDA Orphan Drug Designation in Cutaneous Melanoma

FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC

FDA Accepts NDA for Zanzalintinib/Atezolizumab in Pretreated Metastatic CRC

Apalutamide Reduces Risk of Death by 51% in Metastatic CSPC

Immune System Plays “Big Role” in Multiple Myeloma Development, Care